Research location: “Many inventions, but not necessarily innovation” – Bayer manager calls for new deal for biotech
⚡ Quick Summary
According to Bayer board member Stefan Oelrich, Germany is endangering its innovative strength with low drug prices, too little venture capital - and inertia.
📰 Related Articles
How the Green Party leaders assert themselves against “troublemakers” – and expand their power
Die Welt
Relationship: What is your bedtime routine as a couple?
Die Zeit
Victor Willis: Village People singer Victor Willis is dead
Die Zeit
Coalition leaders discuss reforms - Chancellor Merz optimistic
Tagesschau
Stuttgart car manufacturer: austerity measures at Mercedes - union calls for protest
Handelsblatt